194 results
8-K
EX-99.1
OCUP
Ocuphire Pharma Inc
27 Mar 24
Regulation FD Disclosure
4:26pm
Demonstrated a Favorable Safety and Tolerability Profile Consistent with Prior Studies Total AEs Placebo (n=52) APX3330 (n=51) 120 91 Total treatment … %) 2 (4%) COVID-19 5 (10%) 1 (2%) 0 0 SARS CoV-2 test positive 3 (6%) 0 0 0 APX3330 Safety Profile Ocular AEs similar between APX3330 and placebo Lower
8-K
EX-99.1
OCUP
Ocuphire Pharma Inc
8 Mar 24
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
8:21am
In January 2023, Ocuphire reported top-line efficacy and safety results from the ZETA-1 Phase 2 trial conducted in 103 subjects with DR, including … Scale. APX3330 also demonstrated favorable safety and tolerability in diabetic patients.
In October 2023, Ocuphire held an End-of-Phase 2 meeting
424B3
OCUP
Ocuphire Pharma Inc
16 Feb 24
Prospectus supplement
4:31pm
the potential to be an early, non-invasive treatment for the 8 million NPDR patients in the US.
In January 2023, we reported top-line efficacy and safety … such as PDR is a clinically meaningful endpoint. APX3330 also demonstrated favorable safety and tolerability in diabetic patients. A successful End-of-Phase
8-K
EX-99.2
2y3vg
2 Nov 23
Ocuphire Corporate Presentation November 2023
8:44am
8-K
EX-99.1
17z g59eu0ok
2 Nov 23
Ocuphire Corporate Presentation November 2023
8:44am
8-K
EX-99.1
uwth5cx fspp0693
27 Sep 23
RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024
8:45am
424B5
zmo75
14 Aug 23
Prospectus supplement for primary offering
8:00am
8-K
EX-10.1
4eyun4
11 Aug 23
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
9:27am
8-K
EX-99.1
xwt mmqjj
11 Aug 23
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
9:27am
8-K
EX-99.1
wdx qttmjoqf7
1 Aug 23
Restore Vision & Clarity Ocuphire Corporate Presentation August 2023
11:21am
8-K
EX-99.2
7lvytg
15 May 23
Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update
8:07am
8-K
EX-99.1
cisxhc0t9hk9 ovzio26
15 May 23
Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update
8:07am
8-K
EX-99.1
xswk7
21 Apr 23
Ocuphire Appoints Rick Rodgers as Interim Chief Executive Officer
8:10am